[Department of Error] Department of Error
Khanna D, Denton CP, Angelika Jahreis A, et al. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet 2016; 387: 2630–40—In table 3 of this Article (published online first on May 5, 2016), the p value (placebo vs tocilizumab) for a decrease of 4·7 units or more at 48 weeks should have been 0·25. The interpretation of these data remains unchanged. This correction has been made online as of April 5, 2018.